Isotis and Modex Take the Offensive
With market capitalizations below €40 million, both Modex and IsoTis have lost investors' attention, and have products too small to drive sufficient growth internally. Merging won't solve their size problems immediately, but it gives them a better chance of making the external acquisitions that neither could afford alone.
You may also be interested in...
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.